← All trials
NCT06205056
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Sep 30, 2025
- First posted
- Jan 12, 2024
- Last posted
- Jan 12, 2024
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- United States ArmyLead sponsor
- Henry M. Jackson Foundation for the Advancement of Military MedicineCollaborator
- United States ArmyCollaborator
- Janssen Pharmaceutica NVCollaborator
- Makerere UniversityCollaborator
- Duke UniversityCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.